Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Integrated machine learning analysis for automatic recognition of b-ALL MRD level in flow cytometry list mode data

Yu-Fen Wang, Bor-Sheng Ko, En-Ping Chu et al. Nov 03, 2025 pp. 5143-5143 10.1182/blood-2025-5143

Abstract Introduction Minimal residual disease (MRD) detection by flow cytometry is a powerful prognostic indicator in B...

Voriconazole (VCZ) therapeutic drug monitoring (TDM) for prophylaxis and treatment of invasive fungal diseases in hematology patients – daily clinical practice and evidence from clinical trials

Meinolf Karthaus, Thomas Lehrnbecher, I Karthaus et al. Nov 03, 2025 pp. 2842-2842 10.1182/blood-2025-2842

Abstract Invasive fungal diseases (IFD) are a life-threatening complication during treatment of hematological malignancies. VCZ is approved...

A novel in-frame calreticulin mutation induces activation of JAK-STAT signaling and thrombocytosis

Abigail Runnels, Nicole Arellano, Ling Huang et al. Nov 03, 2025 pp. 358-358 10.1182/blood-2025-358

Abstract Mutations in the gene encoding calreticulin (CALR) represent the second most common genetic abnormality in BCR:ABL negative myelopr...

Hypoxia-driven complement activation expands circulating endothelial cells in transplant-associated thrombotic microangiopathy: A multi-omics single-cell and functional study

Jiaqian Qi, Yan Zhang, Lijun Zhou et al. Nov 03, 2025 pp. 199-199 10.1182/blood-2025-199

Abstract Background Transplant-associated thrombotic microangiopathy (TA-TMA) lacks validated biomarkers and targeted therapies. We hypothes...

Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed/ refractory (R/R) Acute Myeloid Leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial

Thomas Cluzeau, Pierre Yves Dumas, Pau Montesinos et al. Nov 03, 2025 pp. 767-767 10.1182/blood-2025-767

Abstract Background:Crenolanib is a potent type 1 FLT3 inhibitor with activity both as a single agent and in combination with chemotherapy i...

Vmx-C001 has no effect on the anticoagulant function of heparin in healthy subjects

Gerard Short, Michael Zörer, Emma Hilton et al. Nov 03, 2025 pp. 4828-4828 10.1182/blood-2025-4828

Abstract Introduction: VMX-C001 is in clinical development to restore coagulation in patients taking factor Xa direct oral anticoagulants (F...

Next-generation sequencing for myeloid malignancies: Uncovering clinical gaps in physician knowledge and practice

Victoria Harvey-Jones, Keisha Peters, Lisa Lishman et al. Nov 03, 2025 pp. 6422-6422 10.1182/blood-2025-6422

Abstract Background Next-generation sequencing (NGS) is integral to the diagnosis, risk stratification, and treatment selection for patients...

Longitudinal immune dynamics associated with chronic lymphocytic leukemia development in mice with 13q14 deletion and modulation by early BTK inhibition

Patricia Fernández-Guzmán, Iñaki Salvador Corres, Hristo Iliev Iliev et al. Nov 03, 2025 pp. 5656-5656 10.1182/blood-2025-5656

Abstract Background The deletion of 13q14 (del(13q14)) is the most common genetic alteration in Chronic Lymphocytic Leukemia (CLL), found in...

Identification of TPR::FGFR1 fusion in an unusual case of concurrent acute B lymphoblastic leukemia and T-lymphoblastic lymphoma: Case report and review of literature

Heather Greene, Aneeqa Zafar, Elham Vali Betts et al. Nov 03, 2025 pp. 6848-6848 10.1182/blood-2025-6848

Abstract Myeloid/lymphoid neoplasms with FGFR1 rearrangement (MLNAF) are rare, with only approximately 100 cases reported worldwide.1 A wide...

Integrated multi-omics study identifies ursolic acid as a novel therapeutic agent targeting the TNF-α/TAK1/IKKβ/NF-κB axis in hepatic sinusoidal obstruction syndrome

Jie Wei, Yuan Long, Min Wu et al. Nov 03, 2025 pp. 4091-4091 10.1182/blood-2025-4091

Abstract Background Hepatic sinusoidal obstruction syndrome (SOS) is a lethal complication of hematopoietic stem cell transplantation (HSCT)...

High rates of severe maternal morbidity and preterm birth among pregnant individuals with sickle cell disease, a nationwide study from 2020-2024

Aaron Cheng, Kevin Dysart, Heather Burris et al. Nov 03, 2025 pp. 177-177 10.1182/blood-2025-177

Abstract Introduction: Previous data demonstrate that pregnant individuals with sickle cell disease (SCD) face significantly elevated risks...

Therapeutic resistance in aggressive B-cell lymphoma is overcome through the reciprocal enhanced efficacy by CDK9 inhibitors and CAR-T cells

Allen Hu, Qing Yin, Michelle Wang et al. Nov 03, 2025 pp. 7080-7080 10.1182/blood-2025-7080

Abstract Although both CDK9 inhibitors and chimeric antigen receptor (CAR)-T cells have shown significant clinical promise in treating B-cel...

Current clinical concerns for patients with hereditary hemochromatosis – a Delphi consensus study

Jeremy Shearman, Domenico Girelli, Dominik Schaer et al. Nov 03, 2025 pp. 6162-6162 10.1182/blood-2025-6162

Abstract Introduction Hereditary hemochromatosis (HH) is caused by hepcidin dysregulation and is characterized by excessive iron accumulatio...

Patient journey with axicabtagene ciloleucel for relapsed or refractory large B cell lymphoma in Canada: Manufacturing experience and impact of patient location to treatment centre

Sita Bhella, Isabelle Fleury, Christopher Lemieux et al. Nov 03, 2025 pp. 2730-2730 10.1182/blood-2025-2730

Abstract Introduction: Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved...

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Fatima Tuz Zahra, Yumeng Zhang, Sameh Gaballa et al. Nov 03, 2025 pp. 4555-4555 10.1182/blood-2025-4555

Abstract Introduction CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy is approved as second-line treatment for aggressive B-c...

Characteristics, survival, and causes of death in patients with APL from Chile

Andrés Ramírez, Macarena Roa, Carolina Infante O et al. Nov 03, 2025 pp. 6901-6901 10.1182/blood-2025-6901

Abstract Background: Acute promyelocytic leukemia (APL) is prevalent in Latin America and carries a high risk of early-onset complications....

Therapeutic effect of menin inhibitors is reversible in AML treatment and could be enhanced by the targeting of differentiation associated chromatin complex

Zhong Fan, John Mosior, Yanan Jiang et al. Nov 03, 2025 pp. 3295-3295 10.1182/blood-2025-3295

Abstract Menin, encoded by the MEN1 gene, is a chromatin adaptor critical in AML through its role in the MLL complex. Inhibiting the Menin–M...

Detection of minute FLT3-ITD clones at day +30 post-allo-HSCT predicts high relapse risk and informs maintenance therapy in AML: A niche cohort study

Shan Jiang, Dan Feng, Aiming Pang et al. Nov 03, 2025 pp. 589-589 10.1182/blood-2025-589

Abstract Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has improved the prognosis of patients with acute myeloid leukemia (...

Digital preservation following purpura fulminans: A case report

Kai Wang, Ankushi Sanghvi, Kevin Wu et al. Nov 03, 2025 pp. 6675-6675 10.1182/blood-2025-6675

Abstract Background Disseminated intravascular coagulation (DIC) is a complex, life-threatening disorder characterized by systemic activatio...

EZH2 molecular alterations drive micromegakaryocyte expansion in MDS defining a specific high-risk group

Anna Martín Carrizosa, Francisco Beas, Maria Gabarrós et al. Nov 03, 2025 pp. 2084-2084 10.1182/blood-2025-2084

Abstract BackgroundMyelodysplastic neoplasm/syndrome (MDS) subtypes are categorized by genetic aberrations leading to specific morphological...

ALL-pharmacotyping data portal: An open-source platform for exploring genomics of leukemia drug susceptibility and resistance

Karishma Gangwani, Satoshi Yoshimura, Zhenhua Li et al. Nov 03, 2025 pp. 5139-5139 10.1182/blood-2025-5139

Abstract Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, characterized by a multitude of molecular subtypes with vas...

NADPH controls a cell state vulnerability towards ferroptosis in acute lymphoblastic leukaemia

Nikolai Gajic, Rhona Christie, Jordan Martin et al. Nov 03, 2025 pp. 144-144 10.1182/blood-2025-144

Abstract Background and significance: Ferroptosis is a distinct form of non-apoptotic cell death characterised by iron-dependent lipid perox...

Long-term treatment duration and safety of axatilimab among patients with chronic graft-versus-host disease in AGAVE-201

Carrie Kitko, Amandeep Salhotra, Mi Kwon et al. Nov 03, 2025 pp. 6010-6010 10.1182/blood-2025-6010

Abstract Introduction: Chronic graft-versus-host disease (cGVHD) is a major cause of morbidity and non-relapse mortality among patients who...

Incidence and risk factors for new overweight or obesity following hematopoietic cell transplantation for sickle cell disease

Grace Kalmus, Lindsey Abel, Laurence Wechsler et al. Nov 03, 2025 pp. 4283-4283 10.1182/blood-2025-4283

Abstract Longterm outcomes after curative allogeneic hematopoietic cell transplantation (HCT) for sickle cell disease (SCD) are being establ...

Phenotypic landscape and clinical outcomes associated with promotor TERT mutations in patients with telomere biology disorders

Madeline Franke, Terra Lasho, Abhishek Mangaonkar et al. Nov 03, 2025 pp. 4995-4995 10.1182/blood-2025-4995

Abstract Introduction: TERT promoter (pTERT) variants are among the most frequent genetic alterations in human cancers, where they drive onc...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page